[
    {
        "score": -0.5246182680130005,
        "text": "feasibility of a porcine model by perfusing swine limbs\nfor up to 12 h with autologous blood [18]. The same\ngroup later allotransplanted a small series after 12 h of\nex vivo perfusion and showed promising results regard\ufffeing reperfusion injury and muscle contractility. More\ufffeover, it could be shown that muscle contractility\nreturned to nearly normal [19]. A Boston group analyzed\nseven forelimbs of pigs and divided these into two co\ufffehorts of cold perfusion compared to cold storage for 12\nh [20]. In 2016, Ozer and colleagues subsequently in\ufffecreased the perfusion period to 24 h in a porcine model\nof eight limbs and applied normothermic perfusion with\nautologous blood [21]. However, a recent review of the\ncurrent literature on this topic concluded that there is\nno standard protocol for EVLP, and it cannot be clearly\nstated whether the used perfusion solutions are optimal\nfor experimental or clinical vascularized composite tis\ufffesue allotransplantation (VCA) [22]. Additionally, in\n2017, Werner and colleagues from the University of\nMichigan reported the ex situ perfusion of five human\nlimb allografts from deceased heart-beating donors,\nwhich was feasible for up to 24 h with only small signs\nof tissue deterioration [23]. In summary, the limitations of\nthe current literature are that there is no standardized per\ufffefusion protocol, and there are no data available indicating\nthe effects of different perfusion solutions and tempera\ufffetures, the various involved cell types (e.g., endothelial cells,\nnerve cells), or graft viability and functionality. Further\ufffemore, a common problem in the aforementioned studies\nwas weight gain during perfusion due to edema, but there\nare currently no data available about the impact of weight\ngain on subsequent replantation or transplantation,\nespecially in humans. A selection of studies on ex vivo tis\ufffesue perfusion is summarized in Table 1. Of note, all stud\ufffeies had perfusion times of no more than 24 h. In the\nmilitary setting, the necessity for longer perfusion periods\nis highly likely due to strategic evacuations to Role 4 facil\ufffeities. In our experience from the Afghanistan missions, the\naverage time between damage control surgery in the Role\n3 facility and strategic evacuation to the Role 4 facility in\nGermany was 48\u201372 h.\nPresentation of the hypothesis\nThe current lack of replantation possibilities in military\noperations with high rates of amputation could be ad\ufffedressed with the development of a portable, clinically ap\ufffeplicable EVLP device. There are several opportunities\npresent with the introduction of EVLP on the horizon.\nCritical ischemic time\nFirst, EVLP is able to notably prolong the ischemic\nperiods. After recovering the amputated limb, it can\nbe conserved in the perfusion device under physio\ufffelogical conditions until the damage control surgery\nhas been performed and the patient stabilized. Cur\uffferently, the \u201clife before limb\u201d approach is unquestion\ufffeably feasible and even recommended. Therefore,\nEVLP is associated with higher tactical and strategic\nflexibility. Strategic aeromedical evacuation can be\nplanned and executed cautiously without the pressure\nof time, and definitive care in a Role 4 facility can be\ncarefully planned.\nTable 1 Selection of previous studies on ex vivo perfusion in solid organs and extremities\nWorking group Year of publication Characteristics\nWarnecke et al. (Hannover, Germany) [14] 2012 Pilot study on the human application of normothermic\nEVP in lung transplantation\nWarnecke et al. (Hannover, Germany) [15] 2018 Results of the first randomized trial on the human\napplication of normothermic EVP in lung transplantation\nNasralla et al. (United Kingdom) [16] 2018 Results of the first randomized trial on normothermic EVLP\nin liver transplantation\nConstantinescu et al. (Bern, Switzerland) [18] 2011 Feasibility study of EVLP in a porcine model, 16 porcine\nforelimbs perfused for up to 12 h",
        "chunk_id": 4,
        "paper_title": "HYPO TH E SI S Open Access",
        "doi": "10/1186/s40779-020-00250-y",
        "year": 2008.0,
        "filename": "10_1186_s40779-020-00250-y.txt"
    },
    {
        "score": -0.7471191883087158,
        "text": "Resch et al. Machine Perfusion for Marginal Organs\nFIGURE 1 | The past, present, and potential (near) future of organ preservation. Whereas, static cold storage (SCS) has been successfully applied over decades with\ngood outcomes in standard criteria donor (SCD) organs, at present, marginal or expanded criteria donor (ECD) organs in particular are increasingly preserved by\nhypothermic (HMP) or normothermic machine perfusion (NMP) technologies. After initial cold perfusion [*and optimally following normothermic regional perfusion\n(NRP) in Donation after cardiac death (DCD) organs], machine perfusion is commenced either at the retrieval center or at the transplant center in a \u201cback to hub\u201d\napproach. The next step is to effectively use the prolonged preservation times of ECD grafts achieved by optimized machine perfusion protocols to characterize ECD\norgan quality and transplantability via the assessment of biomarkers. To improve graft quality, NMP provides an ideal platform for future immunomodulatory\nmodifications and organ repair.\nso far), hypothermic preservation with/without oxygen, and\nnormothermic perfusion. Normothermic regional perfusion\n(NRP) is mentioned in Figure 1, as it has become an important\ntool for use before the procurement process of DCD starts. The\nfollowing sections will not present NRP data in particular, as the\nreview is about machine preservation in marginal donor organs.\nHowever, good and satisfying results after kidney, pancreas,\nheart, and liver transplantation were reported by several groups\nin the United Kingdom, Spain, and France and have been\nsummarized by previous reviews (37\u201342).\nRecently, Ruiz et al. presented a series of 46 livers transplanted\nafter NRP and concluded that their results, including 23%\nearly allograft dysfunction, are superior to standard DCD organ\nprocurements and comparable to donation after brain death\n(DBD) results (43). The Cambridge group (United Kingdom),\nclear NRP proponents, commented on this publication in a way\nsimilar to our suggestions illustrated in Figure 1. The publication\nby Ruiz et al. (43), like many others before it, did not compare the\nresults to an adequate prospectively organized control group.\nIt is noteworthy that, only recently, a protocol for NRP\nwas established even for DCD heart transplantation. Due to a\nrestoration of function of the arrested heart, organ assessment via\nechocardiography, pressure-volume loops, and cardiac-output\nmeasurements could be implemented (44).\nAccepted criteria for subsequent heart transplantation after\nweaning from mechanical support are defined as: cardiac\nindex >2.5 L/min/m2\n; central venous pressure < 12 mm Hg;\npulmonary capillary wedge pressure < 12 mm Hg; left ventricular\nejection fraction > 50% in transoesophageal echocardiography.\nNRP leads to a meaningful increment of survival benefits and\nhelps to enlarge the available donor pool by utilizing marginal\ndonor organs in a safe way (45, 46). Future trials are needed to\ncompare DCD organ transplantation +/\u2013 NRP followed by +/\u2013\na combination of preservation techniques (42, 45).\nSince 2009, dynamic cold storage\u2014hypothermic machine\nperfusion (HMP)\u2014has progressed to become clinical routine in\nseveral fields of SOT\u2014above all, in kidney preservation. Moers\net al. published their landmark paper in the New England Journal\nof Medicine and demonstrated a significantly lowered DGF\nrate in recipients receiving a hypothermically perfused kidney\ncompared to a renal graft stored on ice in the common way\n(47). Applying the same technology (HMP without supplemental\noxygenation), numerous publications on DCD and ECD kidneys\nhave followed over the past 10 years, showing similar results:\nECD and DCD kidneys and their recipients clearly benefit from\nMP as long as the duration of cold ischemia time (CIT) is\nreasonable (48\u201352). During the second half of the recent decade,\noxygen as a supplement has been focused on for kidney HMP.\nIn 2016, Jochmans et al. published an overview of ongoing",
        "chunk_id": 8,
        "paper_title": "published: 12 May 2020",
        "doi": "10/3389/fimmu/2020/00631",
        "year": 2020.0,
        "filename": "10_3389_fimmu_2020_00631.txt"
    },
    {
        "score": -0.8773042559623718,
        "text": "(Continued from previous page)\nConclusions: The type and volume of fluid used for perioperative management need to be individualized\naccording to the patient\u2019s hemodynamic status and clinical condition. The amount of fluid given should be guided\nby well-defined physiologic targets. Compliance with a predefined hemodynamic protocol may be optimized by\nusing a computerized system. The type of fluid should also be individualized, as should any drug therapy, with\ncareful consideration of timing and dose. It is our perspective that HES solutions remain a valid option for fluid\ntherapy in the perioperative context because of their effects on blood volume and their reasonable benefit/risk\nprofile.\nKeywords: Colloid, Balanced crystalloids, Fluid responsiveness, Hemodynamic monitoring, Acute renal failure, Outcome\nBackground\nPerioperative fluid therapy is a routine aspect of daily\nclinical practice for most anesthesiologists but remains a\ntherapeutic challenge. One of the most complex aspects\nof perioperative fluid therapy is determining how much\nfluid to give each patient. Numerous observational studies\nhave reported a strong association between both excessive\nand insufficient perioperative fluid administration and an\nincreased risk of postoperative complications [1\u20136]. As it is\ndifficult to predict or anticipate the volume of fluids a pa\ufffetient will need during surgery, several national and inter\ufffenational societies recommend using goal-directed fluid\ntherapy (GDFT) based on advanced hemodynamic moni\ufffetoring in patients undergoing high-risk surgery [7\u201310].\nGDFT has been promoted as helping to standardize fluid\nadministration using recommended and validated proto\ufffecols, thereby improving patient outcomes and decreasing\ncosts [11\u201313]. Despite an abundance of literature on this\ntopic, the volume of fluid that should be administered to\nachieve and maintain normovolemia is still the subject\nintense controversy.\nThe choice of intravenous fluid type has also been a\nsubject of passionate debate, recently refueled by the\npublication of several large, prospective, randomized\nstudies in different patient populations. These studies\nhave demonstrated the impact of intravenous fluid solu\ufffetions on patient outcomes, particularly in critically ill pa\ufffetients in the intensive care setting [14]. Although their\nresults have created intense controversy, these studies\nhave clearly demonstrated that the need for intravenous\ninfusions may vary considerably in a given patient during\nthe course of his/her clinical course [15]. They have also\nindicated that results observed in critically ill patients can\ufffenot be extrapolated to surgical patients. The R.O.S.E. con\ufffeceptual model (Resuscitation, Optimization, Stabilization,\nEvacuation) condenses precisely a dynamic approach of\nfluid therapy allowing to maximize its benefits while redu\ufffecing its harms [16]. Importantly, surgical patients receiv\ufffeing i.v fluids in the perioperative setting are typically in\nthe \u201cOptimization phase\u201d and this specific category of pa\ufffetients will be discussed in the present review. Therefore,\nthe goal of this narrative review article is to discuss the\nfundamentals of perioperative fluid therapy through four\nfrequently asked questions regarding perioperative fluid\ntherapy.\nMain text\nQuestion 1: should we administer fluids in a goal-directed\nfashion?\nYES.\nThere is quite strong evidence to support the benefits\nof GDFT in high-risk patients undergoing major surgical\nprocedures [9, 11]. Indeed, over the past 15 years, several\nmeta-analyses of the impact of GDFT in patients under\ufffegoing moderate and high-risk surgeries have observed\nthat GDFT improves outcome compared with routine\ncare [8, 11, 17\u201320]. However, the studies included in\nthese meta-analyses are highly heterogeneous, with dif\ufffeferent protocols, different physiologic endpoints, and\ndifferent technologies to measure stroke volume and\ncardiac output. Interestingly, these studies demonstrate",
        "chunk_id": 1,
        "paper_title": "Hydroxyethyl starch for perioperative goal\ufffedirected fluid therapy in 2020: a narrative",
        "doi": "10/1186/s12871-020-01128-1",
        "year": 2020.0,
        "filename": "10_1186_s12871-020-01128-1.txt"
    },
    {
        "score": -1.399594783782959,
        "text": "Hypothermic ex-vivo perfusion of the kidney produced\nimpressive results and resulted in increases in the number\nof organs available for transplantation. Similar advances\nhave not translated to liver transplantation, however, where\nSCS remains the prominent preservation modality outside of\nclinical trials. Unlike kidneys, livers have a much higher met\ufffeabolic activity and tolerate prolonged ischemia poorly. With\ntheir high metabolic demand, donor livers have been more\nchallenging to perfuse and sustain under normothermic con\ufffeditions. Research into normothermic ex-vivo perfusion has\ncontinued over the last five decades. With advancements in\nthe perfusion technology and the understanding of organ\nphysiology, it has seen renewed interest as a platform to pre\ufffeserve, assess and potentially repair marginal donor organs.10\nThere are a number of devices currently in clinical use for\nthis procedure, including the Organ Assist\u2019s Liver Assist (with\nan adjustable temperature range from 108\n\u2013388 C; for per\ufffeformance of hypothermic and normothermic perfusion),11 the\nOrganOx Metra (normothermic perfusion)12 and the Trans\ufffemedics OCSTM Liver Portable Perfusion System (normother\ufffemic perfusion).13 Overall, these systems consist of a hepatic\nartery +/\u2212 portal vein pump, a perfusate reservoir and an\noxygenating chamber of oxygenated perfusion (Fig. 1).\nAlthough there is ongoing debate over the best preserva\ufffetion/perfusion temperature, normothermic (liver) machine\nperfusion (NMP or normothermic machine liver perfusion)\nappears to be gaining more traction and acceptance, compared\nto subnormothermic perfusion and hypothermic machine\nperfusion (HMP). It is, thus, likely to become the standard of\nex-vivo machine perfusion. Regardless of approach, it has\n276 Journal of Clinical and Translational Hepatology 2018 vol. 6 | 276\u2013282\nCopyright: \u00a9 2018 Authors. This article has been published under the terms of Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0), which\npermits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided. \u201cThis article has been published\nin Journal of Clinical and Translational Hepatology at DOI: 10.14218/JCTH.2017.00048 and can also be viewed on the Journal\u2019s website at http://www.jcthnet.com\u201d.\nKeywords: Liver; Transplantation; Ex-vivo perfusion.\nAbbreviations: DCD, donation after cardiac death; ECMO, extracorporeal\nmembrane oxygenation; HMP, hypothermic machine perfusion; IRI, ischemia\ufffereperfusion injury; NMP, normothermic machine perfusion; SCS, static cold\nstorage; UW, University of Wisconsin solution.\nReceived: 19 July 2017; Revised: 7 February 2018; Accepted: 1 March 2018\n*Correspondence to: Clifford Akateh, General and Gastrointestinal Surgery,\nDepartment of Surgery, The Ohio State University Wexner Medical Center, 395\nW 12th Ave, Room 654, Columbus, OH-43210-1267, USA. Tel: +1-614-293-\n8704, Fax: +1-614-293-4063, E-mail: clifford.akateh@osumc.edu",
        "chunk_id": 1,
        "paper_title": "Normothermic Ex-vivo Liver Perfusion and the Clinical",
        "doi": "10/14218/JCTH/2017/00048",
        "year": 2018.0,
        "filename": "10_14218_JCTH_2017_00048.txt"
    },
    {
        "score": -2.220282554626465,
        "text": "Resch et al. Machine Perfusion for Marginal Organs\nin liver transplantation trials. While the current practice might be\nreasonable in the sense that it is building on the combination of\nparameters currently best established, alternatives are needed but\nneed to be more formally established prior to considering them\nnew clinical standards.\nA Brief History\nThe original vision of organ preservation as formulated in 1813\nwas built on the continuation of circulation and blood supply\n(72). The substitution of blood with perfusion solutions led to\nprolonged successful preservation of tissues, as described by\nCarrell (73). While prolonged successful preservation of tissues\nseems plausible according to these early findings, the actual\nsuitability for transplantation remained to be established (72).\nSuccessful kidney preservation for 3 to 5 days was achieved by\nthe use of continuous perfusion with cooled, oxygenated blood\nor plasma (74). Since continuous warm perfusion, oxygenation,\nand nutrition of an organ during transportation was technically\nvery demanding, the alternative concept eventually surpassed MP\nin the 1960s. The chemical composition of advanced solutions\nfor hypothermic organ storage resulted in excellent short-term\npreservation with good outcomes after transplantation. As with\nany achievement, the good results are a blessing and a curse.\nWith patient and graft survival as the only hard endpoints for\nclinical trials, the room for improvement became very small\u2014\nat least with standard criteria organs. The search for superior\ntechnologies found a platform for clinical realization only when\nthe results after transplantation became less convincing, with a\ngreater effect on bile ducts as a target for early damage in liver\ntransplantation (72, 75\u201377). The organ shortage, together with\nthe push to use lower-quality organs and organs with additional\ndamage as a result of DCD, triggered the clinical realization of\nMP in liver transplantation.\nCurrent Situation\nThe current status of organ preservation remains largely defined\nby SCS. The well-established and standardized procedures of\norgan storage in three sterile plastic bags filled with preservation\nsolution (bag 1) or saline/ringer lactate/other (bags 2/3) is well\ufffeestablished, with a relatively good understanding of the risk\naccumulating with the duration of preservation. The major\nadvantage of SCS is the safety of the procedure. Pretty much\nnothing can happen to an organ in plastic bags, on ice, in\na plastic container. The major limitations of this technique\nrelate to the fact that metabolism continues\u2014even though\nat a very low rate\u2014eventually resulting in the accumulation\nof succinate and reactive oxygen species (ROS) (78\u201381). The\nimmediate exposure to normothermia and oxygen results in an\ninflammatory response and organ-specific damage early after\ntransplantation. The mechanisms responsible for the eventual\norgan damage not only in organ transplantation but also in\nother diseases such as cardiac infarction and stroke are well\ufffeestablished but not are the focus of this review. The key question\nin the consideration of NMP as an alternative to SCS is how\neffectively the mechanisms leading to an IRI are interrupted\nthrough either immediate NMP or NMP following SCS. While\npreclinical evidence (81) and the phase II/III trial by Nasralla et al.\n(62) have delivered evidence suggesting that NMP is superior to\nSCS when applied immediately, the actual net benefit of NMP\nfollowing SCS remains to be more clearly established. While\na key elements in such assessments are the proper definition\nof and agreement in the community on suitable endpoints\nregarding the preservation quality, the accompanying benefits\nand alternative endpoints should not be overlooked. The major\nbenefit of NMP vs. SCS is the time gained with (as it appears)\na relatively safe prolongation of preservation times under close\nto physiological conditions. The ability to monitor the viability",
        "chunk_id": 12,
        "paper_title": "published: 12 May 2020",
        "doi": "10/3389/fimmu/2020/00631",
        "year": 2020.0,
        "filename": "10_3389_fimmu_2020_00631.txt"
    },
    {
        "score": -2.2319869995117188,
        "text": "Scientific Reports | (2020) 10:6063 | https://doi.org/10.1038/s41598-020-62979-9 5\nwww.nature.com/scientificreports/ www.nature.com/scientificreports\nDiscussion\nThe present prospective pilot non-randomized clinical study suggests how hypothermic oxygenated machine \nperfusion results effective and safe in both liver and kidney transplantation. While administration of oxygen \nthrough machine perfusion for liver preservation was largely investigated in a previous clinical study20, few \nreports described HOPE in KT21. Since 1964, several in vivo and preclinical studies report the oxygen use in \nhyperbaric and normobaric conditions to perfuse renal grafts22,23. Here, we report the first clinical trial of HOPE \nin kidney transplant, reporting safety and efficacy in reducing ischemic preservation injuries.\nThe use of the same perfusion device for liver and kidney grafts results as one of the most innovative find\ufffeing of the present study compared to other previous studies11,13,14,24: organ perfusion with this machine is easily \nperformed and it may be initiated at the time of surgical graft preparation during the \u201cback-table\u201d procedures, \navoiding unnecessary CIT extension.\nAn increasing number of researches suggest how the beginning of hypothermic oxygenated perfusion soon \nafter graft retrieval promotes the reduction of waste products, such as succinates, that usually accumulate in the \ngraft during static storage, and increasing the restoring of mitochondrial function25,26.\nOur protocol begins with a 30\u201340 minutes graft washing during organ preparation, with the aim to remove \nwaste products commonly released and accumulated during ischemia time. Furthermore, we equipped our organ \nperfusion system with an adsorbing hemofilter able to remove cytokines and to avoid fat embolism. After the \nwashing phase, oxygenation of the preservation solution begins, with recirculation of the same fluid. We believe \nthis strategy may replace the necessity to immediately start graft perfusion at the end of the retrieval, if CIT is \nmaintained low, as in our study. Metabolites quantification in the perfusates during the flushing phase, compared \nto the usual perfusion time, may demonstrate the benefit of the washing strategy prior to recirculation of HOPE. \nThe limit of our study is due to the lack of these data.\nThe missing of additional perfusates at regular times during perfusion, may represent a further limitation: a \nregular analysis of perfusates could be helpful to better understand organ metabolism during perfusion.\nIn the present study no adverse events were reported as a consequence of perfusion treatment and the out\ufffecome was excellent, with no occurrence of graft dysfunction in HOPE-L despite advanced donor age. No graft \nfailure was registered in HOPE-K, and only two cases had DGF. Moreover, recipients in HOPE-K with DGF \nhad undergone perfusion treatment for less than two hours, as compared to non-DGF patients which actually \nunderwent perfusion treatment for more than 2hours. Therefore, based on our experience, we suggest that kidney \nperfusion should last at least two hours; this treatment time could be possibly longer, as suggested by a pre-clinical \nstudy27.\nThis clinical series \u2013 to the best of our knowledge \u2013 is the first report of HOPE in ECD kidney transplantation; \ntherefore, there are no data about renal preservation issues to compare our results with. Similarly to HOPE-L \nwhich is performed for at least one-hour, HOPE for renal grafts should last at least two hours, but future rand\ufffeomized trials are needed to clarify this hypothesis11.\nMany studies, even from our center, showed that hypothermic oxygenation during organ perfusion is able to \nrestore ATP levels in liver and kidney grafts, improving the functional recovery after transplantation19,28,29. Our \nclinical results showed a better liver function with HOPE compared to SCS in the setting of marginal donation,",
        "chunk_id": 7,
        "paper_title": "Scientific Reports | (2020) 10:6063 | https://doi.org/10.1038/s41598-020-62979-9 1",
        "doi": "10/1038/s41598-020-62979-9",
        "year": 2020.0,
        "filename": "10_1038_s41598-020-62979-9.txt"
    },
    {
        "score": -2.9934158325195312,
        "text": "Scientific Reports | (2020) 10:6063 | https://doi.org/10.1038/s41598-020-62979-9 7\nwww.nature.com/scientificreports/ www.nature.com/scientificreports\nthe analyses of the long-term results of this clinical series could be of interest, as well as other similar research \nstudies with higher sample size.\nSimplicity, outcome benefits for liver and kidney transplantation and low-costs equipment are the winning \npoints of our HOPE system. The safety of our new machine perfusion system was confirmed by the absence of \nadverse events and by the observation that liver hypothermic oxygenation could be effective to improve graft \nfunction, similarly to other reported series in the setting of normothermic blood perfusion30,33.\nWe also measured different markers in perfusates at the beginning and the end of perfusion procedure. \nRegarding KT, NGAL resulted a positive predictive biomarker of renal outcomes at 1st, 3rd and 6th month of fol\ufffelow up: despite NGAL is largely known as a marker for acute and chronic renal injuries34\u201336, this result partially \ncorrelates with our previous findings, suggesting the role of NGAL as an immunomodulatory molecule, able to \npromote immune tolerance through regulatory T cells (Treg)37,38 therefore favoring better clinical outcomes.\nIn LT, significative differences of all perfusate markers were reported when measured at the end of perfusion if \ncompared with the beginning. Recently Dutkosky et al.\n39 demonstrated that mitochondrial flavin levels in perfu\ufffesates during hypothermic oxygenated perfusion might be a marker of better liver graft function. Our preliminary \nresults confirm the relevance of markers in the perfusate and the fact that perfusate analysis is a further tool to \npredict clinical grafts outcomes. We are currently exploring a new field where further studies involving a larger \nsample size and a more comprehensive panel of biomarkers are needed, with the aim to detect optimal targetable \nmarkers to correlate with graft function or to confirm the results of Zurich center.\nSummarizing, we consider our innovative system as a functional tool to allow marginal grafts transplanta\ufffebility, with the aim to reduce utilization avoidance of grafts which are actually discarded19,40,41. Moreover, the \nanalysis of the perfusate may help to evaluate organ viability even in hypothermic conditions, and the infusion of \ntherapeutic agents \u2013 e.g. nutrition, mesenchymal stromal cells (MSC) and extracellular vesicles releasing by MSC, \nanti-inflammatory and anti-apoptotic additives \u2013 might be a simple implement of the perfusion system in use42\u201345.\nFuture trials exploring this field must confirm not only safety and benefits, but also cost effectiveness, as some \nperfusion strategies are still associated with exorbitant costs.\nIn conclusion, HOPE for ECD-DBD grafts is safe and effective in reducing preservation injury and in improv\ufffeing graft function and outcomes for kidney and liver transplantation. Future randomized clinical studies with a \nrepresentative sample size are needed to confirm our results and hypothesis.\nMethods\nStudy design. This national, single-center, prospective interventional arm with a retrospective case-con\ufffetrolled arm, pilot non-randomized clinical study was performed at the General Surgery and Transplant Unit of \nUniversity of Bologna Sant\u2019Orsola - Malpighi Hospital in accordance to the Helsinki Declaration. Ethical approval \nwas obtained by local committee of University of Bologna Sant\u2019Orsola - Malpighi Hospital in June 2016. The \nenrolment process of the interventional study arm was planned considering one procedure per month (liver or \nkidney perfusion before transplantation) following the inclusion criteria in the period from October 2016 to \nDecember 2017. The study was meant to evaluate the safety of a new machine perfusion system, and therefore we \ndecided to monitor adverse events after each procedure for the first 30 post-operative days before enrolling other",
        "chunk_id": 10,
        "paper_title": "Scientific Reports | (2020) 10:6063 | https://doi.org/10.1038/s41598-020-62979-9 1",
        "doi": "10/1038/s41598-020-62979-9",
        "year": 2020.0,
        "filename": "10_1038_s41598-020-62979-9.txt"
    },
    {
        "score": -3.227363348007202,
        "text": "Scientific Reports | (2020) 10:6063 | https://doi.org/10.1038/s41598-020-62979-9 8\nwww.nature.com/scientificreports/ www.nature.com/scientificreports\nCombined organ transplant, donors or recipients with vascular anomalies, urgency transplants and \nre-transplantations were excluded from the study enrollment.\nOrgan retrieval and transfer. Livers/kidneys were harvested in a standard fashion and according to our \npolicy for ECD5,50\u201352. At the end of the retrieval procedures, the organs were stored in cooling sterile bag with \nnew SCS solution and transported to the transplant hospital, where we started the perfusion protocol in the study \ngroup.\nLiver graft histopathological analysis. In order to verify the homogeneity between HOPE-L and SCS-L \ngroups, as well as between HOPE-K and SCS-K groups, the graft histopathology was revised by two different \npathologists in all cases.\nHypothermic oxygenated perfusion. After notification to the Health National System for the clinical use \nin organ perfusion, an innovative machine perfusion developed and described in a previous experimental study19\nwas used to perform ex-vivo hypothermic oxygenated perfusion.\nThis machine perfusion is composed by two pump units that produce a continuous and pulsatile flow to the \nvein or artery respectively, which is set at high values for liver perfusion (median value over 100mL/min) and at \nlower values for kidney perfusion (median value minor to 60mL/min).\nBefore HOPE set-up, the inner and outer sterile flow tubes were connected to the medical devices and the \npriming phase was started. Belzer University of Wisconsin machine perfusion solution was used for priming \nand organ perfusion steps. At the begin of surgical back-table, portal vein or renal artery were cannulated with \nspecial cannulas for organ perfusion of different sizes (8\u201312 F for kidney and 18\u201324F for liver). Each organ was \nconnected to the perfusion device through the attachment of the vascular cannula to the inner perfusion tubes, \nalready assembled to the machine. HOPE was performed at 4 \u00b0C, with a portal vein pressure of 5mmHg or renal \nartery pressure of 25mmHg and an oxygen partial pressure (paO2) of 600\u2013750mmHg. Oxygen is provided to the \nfluid perfusion through the addition of a membrane oxygenator to the perfusion circuit. Flow, pressure and tem\ufffeperature values were monitored frequently by the organ perfusion team involved and registered on USB memory \nsupport. Perfusate gas analysis were accomplished every 15 minutes on effluent perfusate samples to measure \npaO2, pH, and lactate production.\nSterility of perfusion treatment under study was tested performing microbial cultures on perfusion fluid \nbefore (T0) and after HOPE (T1).\nHypothermic oxygenated perfusion was performed in two steps: the first one was the flushing of the organ \nwith hypothermic oxygenated solution for a duration of 30\u201340 minutes, and during the second step the organs \nwere moved in a different box to permit recirculation of the perfusate until implantation.\nGraft flushing started at the beginning of the back-table phase, thus without increasing the duration of the \nstandard surgical steps. Flushing was performed with hypothermic oxygenated solution and after 30\u201340minutes \nof graft flushing, the organs were moved in the another organ container to permit recirculation of the oxygenated \nperfusate. The algorithm treatment is reported in Fig.\u00a03.\nTransplantation. According to the conventional procedures, surgical team performed kidney and liver \ntransplants. Renal transplants were accomplished into iliac fossa anastomosing the artery to the external/com\ufffemon/internal iliac arteries, the vein to the external/common iliac veins and the ureter to the bladder over a single \nstent. Orthotopic liver transplantation was performed with \u201cpiggyback\u201d technique preserving the inferior vena \ncava; epato-choledocal anastomoses were performed over T-tube.",
        "chunk_id": 12,
        "paper_title": "Scientific Reports | (2020) 10:6063 | https://doi.org/10.1038/s41598-020-62979-9 1",
        "doi": "10/1038/s41598-020-62979-9",
        "year": 2020.0,
        "filename": "10_1038_s41598-020-62979-9.txt"
    },
    {
        "score": -3.391481399536133,
        "text": "LOS and significantly less perioperative complications\ncompared with a standard management protocol with\npressure-based target parameters.\nThe first evidence that flow-based cardiovascular para\ufffemeters such as CO or oxygen delivery index (DO2I) cor\uffferelate with the outcome in high-risk patients or high\uffferisk surgery was shown by Shoemaker and colleagues\n[23,24]. Although these studies remained controversial,\nsubsequent work confirmed that goal-directed protocols\nfor perioperative management using flow-related para\ufffemeters improve patient outcome [1-3,5-8,25,26]. The\nunderlying mechanisms of the success of GDT are not\nyet entirely clear. Most authors assume that an oxygen\ndebt from decreased blood flow, hypoxia or hypovolemia\nmay cause mitochondrial damage and subsequent organ\ndysfunction [27]. Thus, adequate tissue oxygen supply\nseems to play a key role to prevent adverse patient out\ufffecome. Although blood flow to peripheral tissues is diffi\ufffecult to measure, tissue oxygen supply may be\napproximated using the DO2I. However, the DO2I needs\nto be calculated from information provided by repeated\nblood gas analyses. We therefore decided to use the CI\nas the target variable of the GDT protocol in this study,\nbecause this variable can be easily obtained and continu\ufffeously measured with the arterial waveform analysis\nmethod in a busy intraoperative setting. Together with\nadequate hemoglobin levels and arterial oxygen satura\ufffetion, we considered the CI as an adequate target for\nflow-based GDT.\nThe results of this study are in good agreement with\nprevious trials dealing with goal-directed hemodynamic\noptimization based on flow-related parameters, although\ntarget variables and methods to achieve the goals vary\nwidely in the literature. Lithium indicator dilution was\nused by Pearse and colleagues [1] to determine CO and\nDO2I in patients undergoing major abdominal surgery.\nIn this study, patients in the intervention group were\noptimized postoperatively with colloids and dopexamine\nto achieve a DO2I of 600 ml min-1 m-2. A significant\nreduction in LOS from 29.5 days to 17.5 days and in the\nnumber of patients with complications (69% vs. 44%)\nwere found in comparison to a CVP-based protocol in a\nstandard care group. POSSUM score values and surgical\ninterventions were comparable with the present study,\nTable 5 Complications until hospital discharge\nComplication Diagnostic tools GDT\ngroup\nn = 30\nControl\ngroup\nn = 30\nInfection\nPneumonia Confirmed chest x-ray, WBC > 12 \u00d7 103 or < 4 \u00d7 103 ml-1 1 3\nAbdominal Abdominal CT 1 4\nUrinary tract Dysuria, urine analysis 0 0\nWound Clinical diagnosis 3 8\nRespiratory\nPulmonary embolism CTPA 0 0\nRespiratory support > 24 hours or weaning failure NIV > 24 hours, Re-intubation 2 3\nCardiovascular\nPulmonary edema Auscultation, chest x-ray 0 2\nArrhythmia \u2265 Lown II, \u2265 30 atrial extrasystoles, AF, VF 2 3\nHypotension Mean arterial pressure \u2264 50 mmHg 2 9\nAcute myocardial infarction ECG signs for ischemia, troponin T \u2265 0.03 ng ml-1 0 2\nStroke Clinical diagnosis confirmed with CCT 0 1\nAbdominal\nBowel obstruction No defecation > 4 days 1 2\nUpper gastro-intestinal bleeding Clinical diagnosis, confirmed with endoscopy 1 0\nAnastomotic leak Drainage discharge, abdominal CT, WBC > 12 \u00d7 103 or < 4 \u00d7 103 ml-1 1 3\nRenal\nUrine output < 500 ml/day or required dialysis for\nacute renal failure\nClinical diagnosis 1 5\nPost-operative massive hemorrhage > 300 ml h-1 and/or need of re-operation 0 2\nPerioperative deaths 2 2\nTotal number of complications 17 49\nNumber (percentage) of patients with complications 6 (20%) 15 (50%)\nAF, atrial fibrillation; CCT, cranial computed tomography;CT, computed tomography; CTPA, computed tomography pulmonary angiogram; ECG, electrocardiogram;\nGDT, goal-directed therapy; NIV, non invasive ventilation; VF, ventricular flutter; WBC, white blood cell count.\nMayer et al. Critical Care 2010, 14:R18\nhttp://ccforum.com/content/14/1/R18\nPage 7 of 9",
        "chunk_id": 6,
        "paper_title": "R E S EARCH Open Access",
        "doi": "10/1186/cc8875",
        "year": NaN,
        "filename": "10_1186_cc8875.txt"
    },
    {
        "score": -3.530535936355591,
        "text": "Resch et al. Machine Perfusion for Marginal Organs\nfate of the graft. Hence, in a system with longer-distance organ\nexchange, additional steps and a new routine would need to be\nestablished. The technology and the shifting of the work of the\nbacktable procedure to the retrieving team need to be considered.\nThe alternative approach where the organ is transferred to\nthe recipient center and is then machine perfused is currently\nbeing pursued, but data indicating the actual advantage of this\napproach are lacking (195). For now, NMP serves as a technology\nthat allows one important asset in surgery to be gained: time.\nThe value of time and flexibility is dependent on the regional\ncircumstances but may hold great potential for easing the surgery\nlogistics, working hours, and surgical training but also gives rise\nto higher risks of nighttime procedures. The actual value of time\nin this context, however, requires further attention and needs to\nbe better defined.\nThe consideration of longer-term organ preservation under\nnormothermic conditions further carries the challenge of\ndefining the responsibilities for managing and monitoring the\norgans. Eventually, the working place description of health\ncare workers involved in this will require adoption and formal\ntraining. Standard operating procedures (SOP) and safety\nparameters need to be established for a wider spread use of\nthe technology. It is likely that the advanced technological\nrequirements and the need for 24-h availability of knowhow and\npersonnel would favor the establishment of regional hubs for MP.\nDespite the hype in the field, the clinical adoption of MP is\nslow. In addition to the above-mentioned factors, the lack of\nreimbursement is a stringent limitation in many regions. For the\ntechnology to be reimbursed, the authorities will require hard\nfacts. Hence, the path to more widespread clinical use might\nbe long, and the focus should remain on the demonstration of\nsuperiority regarding the most relevant clinical endpoints.\nOne major important step toward collective advancement in\nthis field would be the definition of data points during and\nafter MP and the establishment of registries for coordinated\ndata collection. Such data points should include the definition\nand terminology of the various time points and actions such as\ncold flush and storage prior to MP, temperature and flow during\nMP, parameters indicating metabolic function and bile/urine\nproduction during MP, second flush, second cold ischemia time,\nand others. One of the hurdles in improving NMP is the\nlarge number of variables added to preservation. Identifying\nthe relevance of individual parameters will require attention\nto the details of the procedure and adequate data collection\nand handling. To the knowledge of the authors, no routine\ndata collection and no consensus toward data points have been\nestablished at present.\nThe decision-making process in MP is relatively arbitrary\nsince the data collected during MP are suggestive but not formally\nestablished as quality-defining parameters. Since the decision to\ntransplant an organ or not is extremely meaningful, great care\nneeds to be applied in the process, and detailed documentation\nof the reasoning for decision making should be carried out. A\ngreater effort toward orchestrated data collection could help to\nstreamline and eventually enhance the robustness of the decision\ufffemaking process.\nThe preference for MP to be used for the preservation\nof marginal organs results from the greater need for\norgan assessment and the greater potential benefit of better\npreservation. This might be particularly true and relevant for\norgans from uncontrolled DCDs, where the circumstances and\nthe accumulated damage to the organs might be less clear. The\nvalue of an additional assessment under these conditions is not\nonly meaningful with respect to the number of additional organs\nfor transplantation but also for preventing the transplantation",
        "chunk_id": 30,
        "paper_title": "published: 12 May 2020",
        "doi": "10/3389/fimmu/2020/00631",
        "year": 2020.0,
        "filename": "10_3389_fimmu_2020_00631.txt"
    }
]